Table 3.

Treatment characteristics of patients treated with and without MoAbs

Non-MoAb (N = 50)
N (%)		MoAb (N = 14)
N (%)		P value
Sex    
Male 28 (56.0) 10 (71.4) .299 
Female 22 (44.0) 4 (28.6)  
Age, median (IQR) 57 (50-67) 54 (47-67) .409 
Diagnosis    
Diffuse large B-cell lymphoma 39 (78.0) 10 (71.4)  
High-grade B-cell lymphoma with MYC and BCL2/BCL6 1 (2.0) 1 (7.1)  
Primary mediastinal B-cell lymphoma 3 (6.0) 1 (7.1)  
Transformed follicular lymphoma 1 (2.0) 1 (7.1) .516 
Mantle cell lymphoma 1 (2.0) 1 (7.1)  
Follicular lymphoma 3 (6.0) 0 (0)  
B-ALL 2 (4.0) 0 (0)  
Number of previous lines of therapy, median (IQR) 3 (3-4) 3 (3-4) .719 
Previous auto HSCT 14 (28.0) 2 (14.3) .487 
Time since auto HSCT, days median (IQR) 428 (255-892) 1221 (734-1707) .267 
CAR T-cell product   .472 
Axicabtagene ciloleucel 23 (46.0) 9 (64.3)  
Lisocabtagene maraleucel 1 (2.0) 0 (0)  
Tisagenlecleucel 23 (46.0) 4 (28.6)  
Other 2 (4.0) 0 (0)  
Unknown 1 (2.0) 1 (7.1)  
CAR T-cell therapy conditioning    
Fludarabine/cyclophosphamide 47 (94.0) 14 (100.0) 1.000 
Bendamustine 1 (2.0) 0 (0)  
Other 1 (2.0) 0 (0)  
Unknown 1 (2.0) 0 (0)  
Time since CAR T-cell infusion, days median (IQR) 162 (65-420) 358 (126-730) .028 
Variant of SARS-CoV-2 infection    
Wild-type 7 (14.0) 0 (0.0)  
Alpha mutation 2 (4.0) 1 (7.1) .046 
Delta mutation 2 (4.0) 2 (14.3)  
Omicron mutation 11 (22.0) 7 (50.0)  
Unknown 28 (56.0) 4 (28.6)  
Number of vaccinations    
0 34 (68.0) 2 (14.3) <.001 
1 2 (4.0) 1 (7.1)  
2 11 (22.0) 7 (50.0)  
3 0 (0.0) 3 (21.4)  
4 3 (6.0) 1 (7.1)  
Comorbidities∗     
Not present 19 (38.0) 6 (42.9) 1.000 
1 comorbidity 17 (34.0) 5 (35.7)  
2 comorbidities 8 (16.0) 2 (14.3)  
≥ 3 comorbidities 6 (12.0) 1 (7.1)  
Leukocyte count (cells per mm3) at COVID-19 diagnosis, median (IQR) 2670 (1720-4200) 2350 (2150-2950) .786 
Lymphocyte count (cells per mm3) at COVID-19 diagnosis, median (IQR) 500 (230-1000) 400 (270-700) .931 
Neutrophil count (cells per mm3) at COVID-19 diagnosis, median (IQR) 1250 (570-2620) 1740 (1245-2045) .470 
Severity of infection    
At home 10 (20.0) 4 (28.6) .493 
Admitted to the hospital 40 (80.0) 10 (71.4) .493 
Admitted to the ICU 15 (30.0) 3 (21.4) .659 
Treatment with MoAbs 0 (0.0) 14 (100.0) <.001 
Type of MoAb    
Bamlanivimab/etesevimab 0 (0.0) 1 (7.1)  
Casirivimab/imdevimab 0 (0.0) 3 (21.4) <.001 
Sotrovimab 0 (0.0) 10 (71.4)  
Treatment with convalescent plasma 13 (26.0) 3 (21.4) .725 
Treatment with viral replication inhibitor 14 (28.0) 4 (28.6) .966 
Treatment with steroids 24 (48.0) 6 (42.9) .733 
Treatment with tocilizumab 5 (10.0) 1 (7.1) .746 
Outcome    
Alive 31 (62.0) 12 (85.7) .095 
Dead 19 (38.0) 2 (14.3)  
Cause of death    
COVID-19 or contributed by COVID-19 16 (32.0) 0 (0.0) .015 
Hematological malignancy 3 (6.0) 2 (14.0) .476 
Non-MoAb (N = 50)
N (%)		MoAb (N = 14)
N (%)		P value
Sex    
Male 28 (56.0) 10 (71.4) .299 
Female 22 (44.0) 4 (28.6)  
Age, median (IQR) 57 (50-67) 54 (47-67) .409 
Diagnosis    
Diffuse large B-cell lymphoma 39 (78.0) 10 (71.4)  
High-grade B-cell lymphoma with MYC and BCL2/BCL6 1 (2.0) 1 (7.1)  
Primary mediastinal B-cell lymphoma 3 (6.0) 1 (7.1)  
Transformed follicular lymphoma 1 (2.0) 1 (7.1) .516 
Mantle cell lymphoma 1 (2.0) 1 (7.1)  
Follicular lymphoma 3 (6.0) 0 (0)  
B-ALL 2 (4.0) 0 (0)  
Number of previous lines of therapy, median (IQR) 3 (3-4) 3 (3-4) .719 
Previous auto HSCT 14 (28.0) 2 (14.3) .487 
Time since auto HSCT, days median (IQR) 428 (255-892) 1221 (734-1707) .267 
CAR T-cell product   .472 
Axicabtagene ciloleucel 23 (46.0) 9 (64.3)  
Lisocabtagene maraleucel 1 (2.0) 0 (0)  
Tisagenlecleucel 23 (46.0) 4 (28.6)  
Other 2 (4.0) 0 (0)  
Unknown 1 (2.0) 1 (7.1)  
CAR T-cell therapy conditioning    
Fludarabine/cyclophosphamide 47 (94.0) 14 (100.0) 1.000 
Bendamustine 1 (2.0) 0 (0)  
Other 1 (2.0) 0 (0)  
Unknown 1 (2.0) 0 (0)  
Time since CAR T-cell infusion, days median (IQR) 162 (65-420) 358 (126-730) .028 
Variant of SARS-CoV-2 infection    
Wild-type 7 (14.0) 0 (0.0)  
Alpha mutation 2 (4.0) 1 (7.1) .046 
Delta mutation 2 (4.0) 2 (14.3)  
Omicron mutation 11 (22.0) 7 (50.0)  
Unknown 28 (56.0) 4 (28.6)  
Number of vaccinations    
0 34 (68.0) 2 (14.3) <.001 
1 2 (4.0) 1 (7.1)  
2 11 (22.0) 7 (50.0)  
3 0 (0.0) 3 (21.4)  
4 3 (6.0) 1 (7.1)  
Comorbidities∗     
Not present 19 (38.0) 6 (42.9) 1.000 
1 comorbidity 17 (34.0) 5 (35.7)  
2 comorbidities 8 (16.0) 2 (14.3)  
≥ 3 comorbidities 6 (12.0) 1 (7.1)  
Leukocyte count (cells per mm3) at COVID-19 diagnosis, median (IQR) 2670 (1720-4200) 2350 (2150-2950) .786 
Lymphocyte count (cells per mm3) at COVID-19 diagnosis, median (IQR) 500 (230-1000) 400 (270-700) .931 
Neutrophil count (cells per mm3) at COVID-19 diagnosis, median (IQR) 1250 (570-2620) 1740 (1245-2045) .470 
Severity of infection    
At home 10 (20.0) 4 (28.6) .493 
Admitted to the hospital 40 (80.0) 10 (71.4) .493 
Admitted to the ICU 15 (30.0) 3 (21.4) .659 
Treatment with MoAbs 0 (0.0) 14 (100.0) <.001 
Type of MoAb    
Bamlanivimab/etesevimab 0 (0.0) 1 (7.1)  
Casirivimab/imdevimab 0 (0.0) 3 (21.4) <.001 
Sotrovimab 0 (0.0) 10 (71.4)  
Treatment with convalescent plasma 13 (26.0) 3 (21.4) .725 
Treatment with viral replication inhibitor 14 (28.0) 4 (28.6) .966 
Treatment with steroids 24 (48.0) 6 (42.9) .733 
Treatment with tocilizumab 5 (10.0) 1 (7.1) .746 
Outcome    
Alive 31 (62.0) 12 (85.7) .095 
Dead 19 (38.0) 2 (14.3)  
Cause of death    
COVID-19 or contributed by COVID-19 16 (32.0) 0 (0.0) .015 
Hematological malignancy 3 (6.0) 2 (14.0) .476 

ALL, acute lymphoid leukemia; auto HSCT, autologous HSCT.

∗

One or more comorbidities present (chronic cardiomyopathy, chronic pulmonary disease, diabetes, liver disease, obesity, renal impairment, smoker).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal